infantile hemangioma
Conditions
Interventions
A:discontinued propranolol directly from 1 month after the hemangioma reaches its maximum regression
B:discontinued propranolol directly from 3 months after the hemangioma reaches its maximum regression
C:discontinued propranolol gradually within 4 weeks from 1 month after the hemangioma reaches its maximum regression
D:discontinued propranolol gradually within 4 weeks from 3 months after the hemangioma reaches its maximum regression
Sponsors
Shandong Provincial Hospital
Eligibility
Sex/Gender
All
Age
No minimum to 0.5 Years
Inclusion criteria
Inclusion criteria: 1. Patients diagnosed as infantile hemangioma according to the criteria of the International Society for the Study of Vascular Anomalies; 2. Patients younger than 6 months with infantile hemangiomas in proliferative phase; 3. Patients with no previous treatment; 4. Patients guardians who give their informed consents, and are willing to accept the trail and follow-up.
Exclusion criteria
Exclusion criteria: 1. Patients with contraindications of propranolol, such as cardiac disease (cardiac dysplasia, bradycardia, arrhythmia, heart failure, and pulmonary hypertension), pulmonary disease (asthma, and pneumonia), hypothyroidism, Raynauds syndrome, pheochromocytoma, and abnormal liver and kidney function; 2. Patients who are allergic to ß-adrenergic receptor antagonist; 3. Patients who are participating in other clinical trails.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| minor relapse; | — |
Secondary
| Measure | Time frame |
|---|---|
| major relapse;adverse events; | — |
Countries
China
Contacts
Public ContactHuo Ran
Shandong Provincial Hospital
Outcome results
None listed